the standard "3+7" regimen
KY-2024-9-140-2
Phase 2 small_molecule active
Quick answer
the standard "3+7" regimen for Newly Diagnosed Acute Myeloid Leukemia (AML) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active